Dataset opportunity
Peter Brehm — Medical Imaging Dataset Opportunity
Moderate medical imaging dataset held by Peter Brehm, usable for Diagnostic AI and Computer Vision.
Score
68.1
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
Data Sharing Agreement
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
Global AI in Medical Imaging market was valued at $2.1 billion in 2025, with a projected CAGR of 23.9% (2026-2035).
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
Medical Imaging Dataset
Modality
Image
Sector
healthcare
Volume
Moderate
Freshness
Periodic
Rarity
High (proprietary)
Accessibility
Restricted
Legal
Owned by the company — GDPR-sensitive (PII review)
Buyer persona
Medical-AI & diagnostic-imaging companies
Peter Brehm holds a specialized Medical Imaging Dataset focused on orthopedic applications, which uniquely combines imaging modalities like X-ray and CT scans with proprietary industrial_data from their implant CAD/CAM designs. This dataset is further enriched with associated `medical_records`, offering rare longitudinal clinical outcomes, making it exceptionally potent for training and validating high-precision Diagnostic AI models for implant performance and patient monitoring.
The business value is significant, tapping into the global AI in Medical Imaging market, which was valued at $2.1 billion in 2025 and is projected to grow at a remarkable CAGR of 23.9%. Despite complex access conditions due to strict GDPR and MDR compliance, the rarity and depth of this dataset—linking clinical, imaging, and industrial IP—present a premium opportunity for AI buyers to develop competitively advanced diagnostic tools. ⚠ Diligence (valuable data, access to negotiate): Clinical and patient data are subject to strict GDPR and Medical Device Regulation (MDR) compliance; Proprietary implant CAD/CAM designs represent core industrial IP; Access to longitudinal clinical outcomes may require coordination with hospital partners · corporate: independent.
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
This evidence collectively proves ownership of a rare, proprietary dataset of medical images linked to the clinical and radiological outcomes of patient-specific orthopedic implants. This unique collection is ideal for medical AI firms developing next-generation diagnostic AI to predict surgical success and assess implant performance. In a market projected to grow at a CAGR of 23.9%, this dataset offers a significant competitive advantage by providing the high-quality, longitudinal data needed to train and validate advanced computer vision models for complex orthopedic procedures.
See dimension details ↓- Dataset Specificity90
dominant 'medical_records', sector healthcare, 3 specific types
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity82
proprietary domain data
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3 evidence hits
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness46
periodic
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value84
fit for Diagnostic AI
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
Buyer demand is extremely high, driven by the rapid 23.9% CAGR of the AI in Medical Imaging market, as AI developers seek unique, high-quality data to gain a competitive edge.
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility0
PII/regulated
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility0
medium difficulty, independent
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3 evidence types, 3 hits
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License62
ownership=company_owned, licensing=gdpr_sensitive
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
independent
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation56
2 data-appetite signals (2 types)
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
surplus=high — proprietary data beyond what's already monetised
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit100
✓ good target — Peter Brehm is an excellent target as it's an SME whose core business is manufacturing orthopaedic implants, and as a by-product, it processes patient-specific CT scan data for custom-made devices, which it does not appear to monetize as a separate data product. Issues: The company charges a flat fee for the 'conception' of a patient-individual device using CT data, which is waived if the implant is ordered. This is a service f
- Deep Qualification90
⚠ needs review — Peter Brehm is a strong data holder candidate; it manufactures orthopedic implants, with a valuable byproduct dataset of medical imaging, proprietary CAD/CAM designs, and clinical outcome data from post-market studies. [licensing restricted]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
This evidence confirms the existence of radiological images from retrospective studies, which are invaluable for training diagnostic AI models to correlate implant types with clinical outcomes.
Industrial data
This confirms a 40-year history of developing proprietary implant designs, providing essential manufacturing and design context that enriches the core imaging data for advanced AI analysis.
Geospatial data
This points to the underlying patient-specific data used for 3D planning and implant customization, a critical component for AI models focused on personalized medicine and surgical planning.
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Peter Brehm Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in Medical Imaging market was valued at $2.1 billion in 2025, with a projected CAGR of 23.9% (2026-2035) (source: Global Market Insights).. Investment score 68.1/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Atriva Therapeutics — Medical Imaging Dataset Opportunity
View opportunity →healthcareAcandis — Medical Imaging Dataset Opportunity
View opportunity →healthcareSedivention — Medical Imaging Dataset Opportunity
View opportunity →Data Academy
Learn before you deal
- Data marketplaces, explained4 min read
- Data licensing, term by term4 min read
- Is Your Data Worth Money?3 min read